A widely used painkiller, ibuprofen, is increasingly being considered for its potential cancer-fighting properties, with experts suggesting it could reduce the risk of various cancers, including those of the womb, bowel, lung, and prostate. This anti-inflammatory drug, commonly used for ailments like headaches and muscle cramps, may also inhibit cancer growth and influence how DNA is structured within cells, potentially enhancing the effectiveness of immunotherapy treatments.

Ibuprofen, classified as a non-steroidal anti-inflammatory drug (NSAID), functions by blocking two crucial enzymes, COX-1 and COX-2, which are responsible for sending pain signals to the brain. These enzymes facilitate the breakdown of fats into prostaglandins, chemicals involved in pain and inflammation, with COX-2 specifically driving inflammatory responses. By interfering with these enzymes, ibuprofen can help to mitigate inflammation and uncontrolled cell growth, including tumor development, according to Professor Ahmed Eldbewidy, a cancer biology and clinical biochemistry expert at Kingston University.

Recent research, highlighted in the European Medical Journal and cited by Professor Eldbewidy, indicates that ibuprofen may lower the risk of endometrial cancer, which is the most prevalent type of womb cancer. A study analyzing data from over 42,000 women aged 55-74 from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial over 12 years revealed a significant finding. Women who consumed at least 30 ibuprofen pills per month exhibited a 25 percent reduced risk of developing endometrial cancer compared to those taking fewer than four tablets monthly. Interestingly, aspirin did not demonstrate a measurable effect in this context. The researchers believe these findings provide new insights into potential chemopreventive strategies, particularly for women with heart disease.

Endometrial cancer typically originates in the lining of the womb, with key modifiable risk factors including being overweight or obese, as excess body fat elevates oestrogen levels which can stimulate abnormal cell growth. Other contributing factors include age, oestrogen-only hormone replacement therapy (HRT), diabetes, polycystic ovary syndrome (PCOS), early or late menopause, and not having children. Symptoms often include abnormal bleeding, pink or brown discharge, and persistent abdominal pain. This disease affects approximately 9,700 women annually in the UK and is sometimes referred to as a